No abstract

Key PointsQuestionAre very thin- or ultrathin-strut drug-eluting stents associated with reduced adverse cardiovascular events in all-comer patients with lesions in small coronary vessels?FindingsIn this small-vessel substudy including 1506 participants of the 3-arm randomized BIO-RESORT trial, patients experienced fewer repeated target lesion revascularizations within 3 years after treatment with ultrathin-strut sirolimus-eluting stents (2.1%) vs previous-generation thin-strut zotarolimus-eluting stents (5.3%).MeaningIn small-vessel lesions, the implantation of the ultrathin-strut sirolimus-eluting stent that is examined in the BIO-RESORT trial may reduce the need for repeated revascularization.

No abstract